insme Promising Therapies Inspired by Urgent Unmet Patient Needs Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," ...

Promising Therapies Inspired by Urgent Unmet Patient Needs 2 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "est ...

Insmed Incorporated (NASDAQ:INSM) Q3 2020 Earnings Conference Call October 29, 2020 8:30 AM ET Company Participants Sara Bonstein - Chief Financial Officer Will Lewis - Chair & Chief Executive Officer Martina Flammer - Chief Medical Officer Roger Adsett - Chief Operating Officer Kevin Mange - Head of Clinical Development Conference Call Participants Ritu Baral - Cowen Martin Auster - Credit Suisse Stephen Willey - Stifel Connor Meehan - Morgan Stanley John McNeil - Goldman Sachs Joseph Schwartz - SVB Leerin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 54-1972729 (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification no.) 700 US Highway 202/206, Bridgewater, New Jersey 08807 (Address of principal executive offices) (Zip Code) For the quarterly period end ...

Financial Data and Key Metrics Changes - The company reported total net revenue for Q2 2020 of $42.5 million, representing a 42% increase year-over-year [17] - Gross margin for the quarter was approximately 77%, with a gross-to-net ratio of about 13% [17] - Adjusted operating expenses were $73.7 million, slightly down from $74.4 million in Q2 2019, indicating a focus on cash discipline [19] - The company ended the quarter with a strong cash position of $641.9 million, bolstered by recent financing [20] Business Line Data and Key Metrics Changes - ARIKAYCE sales showed strong sequential growth despite COVID-19, contributing significantly to the overall revenue increase [16][39] - The company is preparing for a confirmatory study to evaluate ARIKAYCE as a new standard of care in front-line treatment settings [9] Market Data and Key Metrics Changes - The company anticipates approval for ARIKAYCE in Europe by the end of September 2020, expanding its commercial territory [8] - The company is also making progress in Japan, with a New Drug Application submitted for ARIKAYCE [51] Company Strategy and Development Direction - The company is focused on advancing its pipeline, including brensocatib for bronchiectasis and treprostinil palmitil for pulmonary arterial hypertension [15][35] - The management emphasized the potential synergies between its pipeline programs, particularly between NTM and bronchiectasis [61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to adapt to the challenges posed by COVID-19 and highlighted the importance of maintaining patient care [41][63] - The management noted that the index of suspicion for NTM among healthcare professionals has increased, which could lead to more patient referrals as COVID-19 cases decline [112] Other Important Information - The company is preparing for a virtual Research and Development Day on September 30, where more details about its programs will be shared [12][125] - The company has maintained satisfactory inventory levels for ARIKAYCE and has observed no supply chain disruptions [60] Q&A Session Summary Question: Update on pricing strategy for Europe - The company plans to set a price in free pricing markets like Germany and the UK, with a narrow pricing band anticipated [69][70] Question: Expectations for treprostinil palmitil's tolerability profile - The management expects improved safety and tolerability with the dry powder formulation compared to previous nebulized versions [73] Question: Impact of COVID-19 on patient backlog and physician interactions - The management noted that new patient starts are increasing month-over-month, reflecting a return to normalcy, but challenges remain due to COVID-19 spikes [80][83] Question: Geographic distribution of new patient adds during the pandemic - The management acknowledged significant variability across regions, with some areas seeing a rebound in patient engagement as COVID-19 cases decline [90][91] Question: Market size and launch pace in Europe - The management indicated that the initial uptake in Europe may be slower than in the U.S. due to the center of excellence model, but long-term opportunities remain robust [100][101]

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 54-1972729 (State or other jurisdiction ...

Insmed Incorporated (NASDAQ:INSM) Q1 2020 Results Conference Call April 30, 2020 8:30 AM ET Company Participants Sara Bonstein - CFO Will Lewis - Chairman and CEO Roger Adsett - COO Dr. Martina Flammer - Chief Medical Officer Conference Call Participants Connor Meehan - Morgan Stanley Adam Walsh - Stifel Martin Auster - Credit Suisse Ritu Baral - Cowen Joe Schwartz - SVB Leerink Liisa Bayko - JMP Graig Suvannavejh - Goldman Sachs Josh Schimmer - Evercore ISI Operator Good day, and welcome to the Insmed Firs ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 54-1972729 (State or other jurisdictio ...

| --- | --- | --- | --- | --- | |----------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | 2019 Financial Results and Corporate Update February 25, 2020 | | | | | | | | | | | Not for promotional use Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction ...